Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 2:74:102712.
doi: 10.1016/j.eclinm.2024.102712. eCollection 2024 Aug.

Comparative effectiveness of warfarin management strategies: a systematic review and network meta-analysis

Teerapon Dhippayom  1 , Kansak Boonpattharatthiti  1   2 , Warittakorn Kategeaw  3 , Heeseung Hong  3 , Nathorn Chaiyakunapruk  3   4 , Geoffrey D Barnes  5 , Daniel M Witt  3
Affiliations

Comparative effectiveness of warfarin management strategies: a systematic review and network meta-analysis

Teerapon Dhippayom et al. EClinicalMedicine. .

Abstract

Background: The management of warfarin therapy presents clinical challenges due to its narrow therapeutic index. We aimed to evaluate the comparative effectiveness of different management strategies in patients using warfarin.

Methods: PubMed, Embase, Cochrane CENTRAL, CINAHL, and EBSCO Open Dissertation were searched from inception to 8 May 2024. Randomized controlled trials that compared the following interventions: patient self-management (PSM), patient self-testing (PST), anticoagulation management services (AMS), and usual care in patients prescribed warfarin for any indication were included. Risk ratios (RR) with 95% confidence interval (CI) were estimated using a random-effects model. Surface under the cumulative ranking curves (SUCRA) were used to rank different interventions. The certainty of evidence was assessed using the Confidence in Network Meta-Analysis (CINeMA) online platform. This study is registered with PROSPERO (CRD42023491978).

Findings: Twenty-eight trials involving 8100 participants were included, with follow-up periods of 1-24 months. Mean warfarin dosages were 4.9-7.2 mg/day. Only PSM showed a significant reduction of major TE risk compared with usual care (RR = 0.41; 95% CI: 0.24, 0.71; I2 = 0.0%) with moderate certainty of evidence. The 97.6% SUCRA also supported the beneficial effects of PSM over other interventions. The combined direct and indirect evidence showed significantly higher TTR in PSM compared with usual care (MD = 7.39; 95% CI: 2.39, 12.39), with very low certainty. However, direct evidence showed non-significant TTR improvement (MD = 6.49; 95% CI: -3.09, 16.07, I2 = 96.1%). No differences across various strategies were observed in all-cause mortality, major bleeding, stroke, transient ischemic attack, and hospitalization.

Interpretation: PSM reduces the risk of major TE events compared with usual care, tends to improve anticoagulation control, and should be considered where appropriate.

Funding: Agency for Healthcare Research and Quality (grant ID 5R18HS027960).

Keywords: Anticoagulation management service; Self-management; Self-monitoring; Self-testing; Warfarin.

PubMed Disclaimer

Conflict of interest statement

Geoffrey D. Barnes received grants from Boston Scientific and consulting fees from Pfizer, Bristol-Myers Squibb, Janssen, Bayer, AstraZeneca, Sanofi, Anthos, Abbott Vascular, and Boston Scientific. The other authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
PRISMA flow diagram of selected articles.
Fig. 2
Fig. 2
Network geometry of treatment comparisons of warfarin self-care. Abbreviations: AMS = Anticoagulation management service; INR = International normalized ratio; PSM = Patient self-management; PST = Patient self-testing; UC = Usual care. The numbers along the connection lines in each network geometry indicate the number of studies for each direct comparison.
See this image and copyright information in PMC

References

    1. Haas S., Ten Cate H., Accetta G., et al. Quality of vitamin K antagonist control and 1-year outcomes in patients with atrial fibrillation: a global perspective from the GARFIELD-AF registry. PLoS One. 2016;11(10) - PMC - PubMed
    1. Costa L.S.D., Alsultan M.M., Hincapie A.L., Guo J.J. Trends in utilization, reimbursement, and price for DOACs and warfarin in the US Medicaid population from 2000 to 2020. J Thromb Thrombolysis. 2023;55(2):339–345. - PubMed
    1. Lippi G., Mattiuzzi C., Adcock D., Favaloro E.J. Oral anticoagulants around the world: an updated state-of-the art analysis. Ann Blood. 2018;3(49):10–21037.
    1. Abraham N.S., Singh S., Alexander G.C., et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350 - PMC - PubMed
    1. Vinogradova Y., Coupland C., Hill T., Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018;362 - PMC - PubMed

LinkOut - more resources